Evidence map›Paper›PMID 30607583›Full record

ArticleArchives of gynecology and obstetrics2019

Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma.

Maria Lagerstedt, R Huotari-Orava, R Nyberg, L Nissinen, M Farshchian, S-L Laasanen, E Snellman, J U Mäenpää, V-M Kähäri

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Maria LagerstedtDepartment of Dermatology, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland. lagerstedt.maria.e@student.uta.fi.ORCID 0000-0002-5417-2989
R Huotari-OravaFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
R NybergDepartment of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.
L NissinenDepartment of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.
M FarshchianDepartment of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.
S-L LaasanenDepartment of Dermatology, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland.
E SnellmanDepartment of Dermatology, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland.
J U MäenpääFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
V-M KähäriDepartment of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.
Tampere University · FIUniversity of Turku · FITampere University Hospital · FITampere University of Applied Sciences · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe two main etiological factors for vulvar squamous cell carcinoma (vSCC) are the vulvar dermatosis lichen sclerosus (LS) and high-risk human papillomavirus (hrHPV). Serpin A1 (α1-antitrypsin) is a serine protease inhibitor, which plays a role in the tumorigenesis of various cancer types. The aim of the study was to evaluate the expressions of Serpin A1 in LS, premalignant vulvar lesions, and vSCC using immunohistochemistry (IHC) and serum analysis, and to compare Serpin A1 stainings to the tumor markers p53 and p16.

methodsIn total, 120 samples from 74 patients were studied with IHC for Serpin A1, p53 and p16: 18 normal vulvar skin, 53 LS, 9 premalignant vulvar lesions (dVIN/HSIL) and 40 vSCC samples. Serum concentrations of Serpin A1 were analyzed from 30 LS, 44 vSCC and 10 control patients. Expressions were compared to clinical data.

resultsTumor cell-specific Serpin A1 overexpression was detected in 88% of vSCC samples, independent of the etiology. The intensity of Serpin A1 expression was significantly higher in vSCC than in healthy vulvar skin, LS, or premalignant vulvar lesions. Serpin A1 showed an association with p53 positivity. No difference in overall survival was found between Serpin A1-, p53-, or p16-positive vSCC patients. Serum concentrations of Serpin A1 were equal in the LS, vSCC, and control groups.

conclusionTumor cell-specific Serpin A1 overexpression is a potential biomarker in vSCC.

Indexed as

AdultAgedAged, 80 and overalpha 1-AntitrypsinCarcinoma, Squamous CellFemaleHumansMiddle AgedVulvar Neoplasmsalpha 1-AntitrypsinSERPINA1 protein, humanLichen sclerosusp16p53Serpin A1Vulvar squamous cell carcinoma

Identifiers

PMID30607583
PMCPMC6475512
OpenAlexW2908081949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.